Pentoxifylline: Evidence strong enough for renoprotection?

Journal of the Formosan Medical Association

Volumn 115, Issue 8, 2016, Pages 591-592

  Lai, Tai Shuan ^a   Chiang, Wen Chih ^a   Chen, Yung Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR;

CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; MICROALBUMINURIA; NONHUMAN; PROTEINURIA; RENAL PROTECTION; SHORT SURVEY; COMPLICATION; KIDNEY FAILURE, CHRONIC; RETROSPECTIVE STUDY; TAIWAN;

DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROTEINURIA; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84955168191     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2015.12.010     Document Type: Short Survey

References (8)

1. 1 Tsai, T.J., Lin, R.H., Chang, C.C., Chen, Y.M., Chen, C.F., Ko, F.N., et al. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 70 (1995), 91–99.
2. 2 Lin, S.L., Chen, Y.M., Chiang, W.C., Tsai, T.J., Chen, W.Y., Pentoxifylline: a potential therapy for chronic kidney disease. Nephrology (Carlton, Vic) 9 (2004), 198–204.
3. 3 Chen, Y.M., Chiang, W.C., Yang, Y., Lai, C.F., Wu, K.D., Lin, S.L., Pentoxifylline attenuates proteinuria in anti-Thy1 glomerulonephritis via downregulation of nuclear factor-kappaB and Smad2/3 Signaling. Mol Med (Cambridge, Mass) 21 (2015), 276–284.
4. 4 Han, S.J., Kim, H.J., Kim, D.J., Sheen, S.S., Chung, C.H., Ahn, C.W., et al. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetol Metab Syndr, 7, 2015, 64.
5. 5 Navarro-Gonzalez, J.F., Mora-Fernandez, C., Muros de Fuentes, M., Chahin, J., Mendez, M.L., Gallego, M., et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 26 (2015), 220–229.
6. 6 Chen, P.M., Lai, T.S., Chen, P.Y., Lai, C.F., Wu, V., Chiang, W.C., et al. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. J Formos Med Assoc 113 (2014), 219–226.
7. 7 Wu, P.C., Wu, C.J., Lin, C.J., Pan, C.F., Chen, C.Y., Huang, T.M., et al. Pentoxifylline decreases dialysis risk in patients with advanced chronic kidney disease. Clin Pharmacol Ther 98 (2015), 442–449.
8. 8 Lin, S.L., Chen, Y.M., Chiang, W.C., Wu, K.D., Tsai, T.J., Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 52 (2008), 464–474.